课题基金 / 基金详情

项目摘要

项目成果

STEVEN ZHENG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT As a central controller of cancer growth and metabolism, mTORC1 pathway is commonly mutated and activated in human cancer, leading to uncontrolled growth. Cancer cells are ‘addicted’ to elevated mTORC1 signaling, rendering mTORC1 a desirable cancer drug target. The highly specific mTORC1 inhibitors rapamycin analogs (rapalogs, e.g. temsirolimus) are US FDA-approved oncology drugs. However, their clinical response has been moderate, which is in a large part due to incomplete understanding of mTORC1 signaling mechanisms underpinning rapamycin action. In this application, we will test the central hypothesis that nuclear mTORC1 signaling promotes aerobic glycolysis, or Warburg Effect, through a long non-coding RNA (lncRNA) NEAT1- dependent mechanism, which is important for mTORC1-driven tumorigenesis and rapamycin response. A successful completion of this project will provide a deeper understanding of this oncogenic pathway and therapeutic response to its blockage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oncogenic Chromatin Remodeling and Anticancer Mechanisms
Metabolic Control and Anticancer Mechanism
Metabolic Control and Anticancer Mechanism
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
国内基金
海外基金
UMSC-Exo通过调控Ribosome biogenesis诱导心肌再生的策略及机制研究
  • 批准号:
    82370264
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    李杨欣
  • 依托单位:
活体动物线粒体biogenesis、fission及fusion对肝脏再生中能量供应影响机制的研究
  • 批准号:
    81470878
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    柳勤龙
  • 依托单位: